CA
NZ
UK
AU
IND
US
Valneva SE (NASDAQ: VALN) shares closed up 26% at $7.13 after the EMA validated the marketing application for PF-07307405, a Lyme disease vaccine candidate partnered with Pfizer.
Daré Bioscience, Inc. (NASDAQ: DARE) shares closed down 32% at $0.93 after the company announced the pricing of a $6.0 million registered direct offering at $1.37 per share, including concurrent Series A and B warrants.
NeOnc Technologies (NASDAQ: NTHI) shares closed up 31% at $4.22 after the company hosted an investor call highlighting favorable Phase 2a NEO100-01 results for recurrent IDH1-mutant high-grade glioma.
Freenome (NASDAQ:FRNM) shares rose 3.37% in pre-market trading to $11.95, up from a prior close of $11.56, after the U.S. Food and Drug Administration granted Breakthrough Device Designation to SimpleScreen Lung, the company's investigational blood-based lung cancer screening test. The designation applies to the …
Hemab Therapeutics (NASDAQ:COAG) shares rose 5.57% in pre-market trading to $58.00, extending a multi-week rally to fresh 52-week highs following a string of bullish analyst actions after the company's second quarterEarningsreport and pipeline updates. Multiple research firms raised price targets and reiterated Buy ratings …
Ocular Therapeutix (NASDAQ:OCUL) shares rose 15.04% in pre-market trading to $11.55, up from a prior close of $10.04. No company-specific announcement dated today was identified as the driver of the move, and the most recent trading commentary available describes a quiet, largely unchanged session …
SS Innovations International (NASDAQ:SSII) shares rose 3.86% in pre-market trading to $4.04, up from a prior close of $3.89, as investors continued digesting record second quarter 2026 results reported August 13. Revenue rose 39.4% year-over-year to $13.9 million, with installations of the company's SSi …
EyePoint Pharmaceuticals (NASDAQ:EYPT) shares plunged 64.01% in pre-market trading to $5.31, down from a prior close of $14.75, and trading in the stock was halted after the company disclosed that its experimental eye drug, DURAVYU, failed to meet its primary endpoint in the LUGANO …
● VolitionRx Limited filed its second-quarter 10-Q on August 13, 2026 and hosted anEarnings Callthe following morning.
● Vivos Therapeutics reported second-quarter 2026 results on August 14 showing 35% year-over-yearRevenuegrowth.
Please wait processing your request...